hotspot -WSS

hotspot

author：leisure time 2025-09-03 05:28:48 - browse：8

Balance innovation — A federal judge made a key ruling in a lawsuit challenging a new drug pricing program Adobe

WASHINGTON — A federal court judge allowed a new Medicare drug price negotiation program to proceed while the court deliberates whether it is constitutional.

The case centers on Democrats’ new law, which empowered the Medicare program to start negotiating lower prices for certain medicines that are especially expensive for the government. Judge Michael Newman, a Trump appointee to the U.S. District Court for the Southern District of Ohio, ruled against the U.S. Chamber of Commerce, which had sued the federal government and asked for the program to be stopped while litigation continues.

Medicare officials announced the first 10 drugs they would negotiate over last month, and the deadline for the pharmaceutical companies to sign agreements to start bargaining is Oct. 1. The Chamber of Commerce had requested a decision on the preliminary injunction by that date.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

WSS

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Eyeing GLP

Group opposing PBM reform sets lobbying record

Cosmetics set for new safety regulation. Why the industry is on board

At flashy new research hub, AstraZeneca lays out ambitious growth goals

hotspot

hotspot

leisure time

At least 13 dead in Texas as scorching temps continue

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AI can’t replace a physician’s gut feeling

Bright Health sells Medicare Advantage business to Molina

Listen: Wegovy in the brain & pivotal Alzheimer's data

DIEP, the 'gold standard' of breast reconstruction, is under threat

For longer

Walensky prepares to leave CDC — and Congress — behind

ASCO eve: Let’s set the table for this year's meeting

hotspot

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Making the case for fair compensation in clinical trials

Bird flu surveillance in wastewater gets boost from consortium

Bird flu surveillance in wastewater gets boost from consortium

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

focus

hotspot

leisure time

knowledge